Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies - Functional and Presentation Currency (Details)

v3.23.1
Summary of Significant Accounting Policies - Functional and Presentation Currency (Details)
 12 Months Ended
Mar. 31, 2023
Virax Biolabs Group Limited  
Disclosure of reclassifications or changes in presentation [line items]  
Functional Currency U.S. dollars
Virax Biolabs (UK) Limited  
Disclosure of reclassifications or changes in presentation [line items]  
Functional Currency U.S. dollars
Virax Biolabs Limited (FKA- Shanghai Biotechnology Devices Ltd)  
Disclosure of reclassifications or changes in presentation [line items]  
Functional Currency U.S. dollars
ViraxImmune T-Cell Medical Device Company Limited (FKA- Stork Nutrition Asia Limited)  
Disclosure of reclassifications or changes in presentation [line items]  
Functional Currency U.S. dollars
Virax Biolabs Pte. Limited  
Disclosure of reclassifications or changes in presentation [line items]  
Functional Currency U.S. dollars
Logico Bioproducts Corp.  
Disclosure of reclassifications or changes in presentation [line items]  
Functional Currency U.S. dollars
Shanghai Xitu Consulting Co., Ltd (FKA- Shanghai Logico Bioproducts)  
Disclosure of reclassifications or changes in presentation [line items]  
Functional Currency Renminbi
Virax Biolabs USA Management, Inc.  
Disclosure of reclassifications or changes in presentation [line items]  
Functional Currency U.S. dollars